Daniel Burton’s transition deal at Health Catalyst (HCAT) details advisory role
Health Catalyst (HCAT) has outlined a transition agreement with former CEO Daniel Burton, who retired on February 12, 2026. He will serve as a strategic advisor until December 31, 2026, receiving a monthly base salary of $10,000. As part of the agreement, Burton will forfeit unvested restricted stock units and provide a general release of claims against the company.
Health Catalyst CEO Retirement Accelerated With Advisory Role
Health Catalyst CEO Daniel Burton has accelerated his retirement to February 12, 2026, triggering an earlier leadership transition. He will serve as a strategic advisor through year-end 2026, receiving a monthly salary but forfeiting unvested equity. TipRanks' AI Analyst, Spark, rates HCAT as Neutral due to weak financial performance and bearish technicals, despite some positive commentary on adjusted profitability.
Health Catalyst enters transition agreement with former CEO Daniel Burton
Health Catalyst (NASDAQ:HCAT) has finalized a transition agreement with former CEO Daniel Burton, who will serve as a strategic advisor until December 31, 2026, receiving a monthly salary of $10,000. In exchange, Burton forfeits unvested stock units and provides a general release of claims. This news follows mixed Q4 2025 financial results and conservative Q1 2026 guidance, leading to varying analyst opinions and some stock downgrades.
Health Catalyst enters transition agreement with former CEO Daniel Burton
Health Catalyst (NASDAQ:HCAT) has announced a transition agreement with former CEO Daniel Burton, who stepped down on February 12. Burton will serve as a strategic advisor until December 31, 2026, receiving a monthly salary of $10,000, while forfeiting unvested stock units. This news follows mixed Q4 2025 financial results and varying analyst opinions on the company's future.
Health Catalyst names Daniel Burton strategic advisor after accelerating retirement as CEO
Health Catalyst (HCAT) has announced that Daniel Burton's retirement as CEO has been accelerated to February 12, 2026. He will transition into a strategic advisor role for the company through December 31, 2026, receiving an average monthly base salary of $10,000 starting March 1, 2026. This move involves the forfeiture of his unvested RSUs and performance-based RSUs eligible to vest after March 2, 2026.
List of 12 Acquisitions by Health Catalyst (Apr 2026)
Health Catalyst has completed 12 acquisitions, with the most recent being Upfront Healthcare in January 2025 for $86M. The company's peak acquisition years were 2024 and 2020, and its acquisitions primarily target the Healthcare IT and Cybersecurity sectors across the United States and United Kingdom.
Evercore ISI Reaffirms Their Hold Rating on Health Catalyst (HCAT)
Evercore ISI analyst Elizabeth Anderson CFA maintained a Hold rating on Health Catalyst (HCAT) with a $3.00 price target. This follows a similar Hold rating from Wells Fargo, though TipRanks – Anthropic downgraded the stock to Sell. Health Catalyst reported a quarterly revenue of $74.68 million and a GAAP net loss of $91.03 million for the quarter ending December 31.
Vanguard disaggregates holdings; subsidiaries now report separately (HCAT)
The Vanguard Group has filed an amendment (SCHEDULE 13G/A) stating it beneficially owns 0 shares of Health Catalyst (HCAT) common stock, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately. The filing specifies that the internal realignment on January 12, 2026, caused certain subsidiaries to report separately under SEC Release No. 34-39538 and does not indicate a sale of shares but rather an organizational change in reporting.
Health Catalyst, Asure Software, GitLab, Zeta Global, and SoundHound AI Shares Plummet, What You Need To Know
Shares of Health Catalyst, Asure Software, GitLab, Zeta Global, and SoundHound AI plummeted during an afternoon trading session. This sharp decline followed an announcement from Anthropic about its Claude AI assistant gaining the ability to control computers, sparking investor concerns that AI could disrupt legacy software providers. Analysts suggest this "agentic era" could lead to significant margin compression, although opportunities might arise for investors.
If You Invested $1,000 in Health Catalyst (HCAT)
This article analyzes the historical performance of a $1,000 investment in Health Catalyst (HCAT) over 1, 5, and 10 years, showing significant negative returns. It also provides an overview of Health Catalyst, describing its business model, technology ecosystem (Ignite™), and focus on healthcare data, security, and client partnerships aimed at measurable improvements. The company's financial reporting, governance, and strategic initiatives are also discussed for investors tracking HCAT stock.
Health Catalyst, Inc. (NASDAQ:HCAT) Q4 2025 Earnings Call Transcript
Health Catalyst, Inc. (NASDAQ: HCAT) reported its Q4 2025 earnings, missing EPS expectations. New CEO Ben Albert outlined a strategic review focused on strengthening commercial engines, improving retention, increasing efficiency, and leveraging IP to address client needs in cost management, clinical quality, and consumer experience. The company provided Q1 2026 financial guidance but withheld full-year guidance due to ongoing strategic and operational reviews, with intentions to provide it by the Q1 2026 earnings call.
Total debt per share of Health Catalyst, Inc. – FWB:2YP
This article provides financial information for Health Catalyst, Inc. (FWB:2YP) on the Frankfurt Stock Exchange. It specifically highlights the "Total debt per share" metric for the company. The content appears to be a stub or a section of a larger financial data presentation rather than a complete article.
Wells Fargo downgrades Health Catalyst stock rating on structural concerns
Wells Fargo downgraded Health Catalyst Inc. (NASDAQ:HCAT) from Overweight to Equal Weight and cut its price target to $1.00 from $5.00 due to persistent structural concerns. The firm noted that the company has missed expectations on retention stabilization and client growth, indicating deeper fundamental problems beyond replatforming efforts. Despite the significant stock decline and analyst downgrades, InvestingPro analysis suggests the stock may be undervalued.
Health Catalyst Q4 2025 Earnings: Revenue Exceeds Forecasts, Margins Decline - News and Statistics
Health Catalyst (HCAT) reported Q4 2025 revenue of $74.68 million, surpassing analyst estimates despite a year-over-year sales decrease and an earnings miss. The company's operating margin also declined, primarily due to a significant data platform migration, leadership changes, and restructuring efforts. Health Catalyst provided Q1 2026 guidance below expectations and withheld a full-year forecast pending a strategic review aimed at simplifying offerings to improve client retention.
Health Catalyst 2025 Results & 2026 Outlook: Ignite Platform & Growth Strategy - News and Statistics
Health Catalyst executives held a conference call to discuss their 2025 financial results and strategic outlook for 2026, focusing on growth strategies, client relationships, and the Ignite data and analytics platform. Management emphasized the forward-looking nature of their statements, noting potential material differences in actual results and directing listeners to SEC filings for risk factors. The discussion also included non-GAAP financial measures, with a reconciliation made available in the company's press release.
Health Catalyst, Inc. (NASDAQ:HCAT) Short Interest Up 18.1% in February
Health Catalyst, Inc. (NASDAQ:HCAT) saw its short interest increase by 18.1% in February, reaching 6,750,287 shares, representing about 9.8% of outstanding shares. This increase comes as the stock fell around 8% to near a 1-year low, and analysts have trimmed price targets, resulting in a consensus "Hold" rating. The company recently missed quarterly EPS estimates and analysts forecast a negative EPS for the current year.
Health Catalyst, Inc. $HCAT is First Light Asset Management LLC's 7th Largest Position
First Light Asset Management LLC significantly increased its stake in Health Catalyst, Inc. (HCAT) by 9.9% in Q3, making it their 7th largest position, valued at approximately $38.3 million and representing about 19% of the company. Despite slightly beating Q4 revenue expectations, Health Catalyst missed EPS estimates, lowered Q1 guidance, and faced analyst price target cuts, leading to a sharp sell-off. The stock is currently low-priced and volatile with high institutional ownership, and some analysts suggest it may be nearing a bottom for opportunistic buyers.
Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of "Hold" by Brokerages
Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from thirteen brokerages, with an average 12-month target price of $3.16, though several analysts recently cut their price targets. The stock experienced a significant decline following mixed Q4 results, including an EPS miss and lowered Q1 revenue guidance. Despite this volatility, institutional investors hold a substantial 85% of the shares.
Net current asset value per share of Health Catalyst, Inc. – FWB:2YP
The article provides the net current asset value per share for Health Catalyst, Inc. (FWB:2YP). It shows that at the time of publication, the market was closed with no trades. The content primarily focuses on financial data for this specific company.
Health Catalyst Q4 2025 Financial Report: Revenue $74.7M, Loss $91M - News and Statistics
Health Catalyst Inc. reported a significant loss of $91 million in Q4 2025, or $1.28 per share, missing Wall Street's adjusted EPS expectations of 9 cents per share with actual earnings of 8 cents per share. However, the company's Q4 revenue of $74.7 million surpassed analyst forecasts of $73.6 million. For the full year 2025, Health Catalyst reported a loss of $178 million on $311.1 million in revenue and projects Q1 2026 revenue to be between $68 million and $70 million.
Health Catalyst (HCAT) Losses Swell To US$178 Million Challenging Margin Improvement Narrative
Health Catalyst (HCAT) reported FY 2025 results with a net loss of US$178 million, widening from the previous year, despite revenues staying around US$311 million. Analysts predict continued losses for the next three years and a slight revenue decline, challenging the company's narrative of margin improvement. Despite a low P/S multiple, the extended period of unprofitability raises concerns among investors, while bulls hope for future margin expansion and profitability by 2028.
Citigroup Lowers Health Catalyst Price Target
Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.75 to $1.75, while maintaining a "neutral" rating. This decision, echoed by other firms like Stifel Nicolaus and Canaccord Genuity, stems from concerns over the healthcare data and analytics company's financial performance and challenging market conditions. The lowered price targets signal potential headwinds for Health Catalyst's near-term growth and profitability.
Citigroup Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $1.75
Citigroup has lowered its price target for Health Catalyst (NASDAQ:HCAT) from $2.75 to $1.75, maintaining a "neutral" rating, which implies a potential 32.6% upside. This follows a trend of other analysts also trimming their targets for the company. The company's recent Q4 EPS missed estimates and Q1 2026 guidance was below consensus, raising concerns about profitability and growth despite some positive revenue figures for FY2025.
Health Catalyst plummets after mixed Q4; CEO declines to rule out potential sale as part of review
Health Catalyst (HCAT) shares plummeted over 31% after reporting mixed fourth-quarter results, missing earnings estimates but exceeding revenue expectations. The CEO indicated that a potential sale of the company is not being ruled out as part of an ongoing review. Shares were down nearly 28% in early trading hours following the announcement.
Cantor Fitzgerald cuts Health Catalyst stock price target on turnaround uncertainty
Cantor Fitzgerald has lowered its price target for Health Catalyst Inc. (NASDAQ:HCAT) to $3.00 from $4.00, maintaining a Neutral rating due to uncertainty regarding the company's turnaround timing and ongoing pressures from its Ignite transition. Despite this, Health Catalyst exceeded recent revenue expectations, although Q1 2026 guidance suggests a revenue and EBITDA decline. Analysts predict the company will turn profitable this year, and InvestingPro suggests the stock might be undervalued.
Stifel cuts Health Catalyst stock price target on migration woes
Stifel lowered its price target for Health Catalyst Inc. (NASDAQ:HCAT) due to ongoing "Ignite-migration pressures" and weaker-than-expected Q1 fiscal 2026 revenue and EBITDA guidance. The company faces challenges in migrating clients from legacy DOS to Ignite, with significant revenue at risk. Stifel maintains a Hold rating, awaiting more conclusive data, but suggests the company could be an acquisition target given its undervalued status and recent mixed Q4 2025 financial results.
Health Catalyst (NASDAQ: HCAT) 2025 loss widens on major goodwill write-down
Health Catalyst (NASDAQ: HCAT) reported a significantly wider net loss of $177.9 million in 2025, primarily due to a $110.2 million goodwill and intangible impairment charge, despite a modest 1% revenue increase to $311.1 million. While GAAP profitability metrics improved, the company experienced a decline in its Dollar-based Retention Rate (Tech + TEMS) to 93%. Health Catalyst has also withheld full-year 2026 guidance pending a strategic review related to its CEO transition.
Health Catalyst Q4 2025 Earnings: Revenue Beat, Lower Guidance for 2026 - News and Statistics
Health Catalyst reported Q4 2025 earnings, with revenue of $74.68 million beating analyst projections but declining year-over-year. While adjusted EBITDA exceeded expectations, the company provided lower-than-anticipated guidance for Q1 2026 revenue and EBITDA, indicating a potential slowdown in growth despite solid 2025 performance.
Health Catalyst: Q4 Earnings Snapshot
Health Catalyst Inc. (HCAT) reported a fourth-quarter loss of $91 million, or $1.28 per share, missing Wall Street expectations for adjusted earnings. Despite the loss, the company's revenue of $74.7 million for the quarter exceeded analysts' forecasts. For the upcoming quarter ending in March, Health Catalyst anticipates revenues between $68 million and $70 million.
Health Catalyst (NASDAQ:HCAT) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops 10.4%
Health Catalyst (NASDAQ:HCAT) reported better-than-expected revenue in Q4 CY2025, reaching $74.68 million, but its stock dropped 10.4% due to weaker-than-expected revenue and EBITDA guidance for Q1 CY2026. The company also missed non-GAAP profit estimates and showed a negative CAC payback period, indicating inefficiencies in customer acquisition. Despite the Q4 revenue beat, the forward guidance suggests potential demand challenges, leading to an unfavorable market reaction.
Health Catalyst (NASDAQ:HCAT) Announces Quarterly Earnings Results
Health Catalyst (NASDAQ:HCAT) reported Q4 earnings per share of $0.08, missing the consensus estimate of $0.10, although revenue of $74.68 million surpassed expectations. The company remains unprofitable with negative margins and return on equity, and its stock traded down to $1.79, near its 52-week low. Despite significant institutional ownership, analysts maintain a "Hold" rating with a consensus price target of $4.06.
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
Health Catalyst (Nasdaq: HCAT) reported solid financial performance for the fourth quarter and full year 2025, with total revenue reaching $311.1 million and Adjusted EBITDA of $41.4 million. CEO Ben Albert highlighted the company's focus on long-term success and outlined expectations for Q1 2026, including total revenue between $68 and $70 million. The company emphasized its commitment to its mission of igniting smarter healthcare through data and analytics technology and services.
Health Catalyst: Q4 Earnings Snapshot
Health Catalyst Inc. (HCAT) reported a fourth-quarter loss of $91 million, or $1.28 per share, which adjusted to 8 cents per share, missed analyst expectations of 9 cents per share. Despite the loss, the company's revenue of $74.7 million surpassed Street forecasts of $73.6 million. For the full year, Health Catalyst recorded a loss of $178 million on revenue of $311.1 million and expects current-quarter revenue to be between $68 million and $70 million.
Health Catalyst Inc (HCAT) Stock Falls on Q4 2025 Earnings
Health Catalyst Inc (HCAT) reported Q4 2025 results with revenue down 6.19% year-over-year, missing consensus estimates. The company's stock fell 19.42% despite improved gross profit, due to continued unprofitability and significant declines in cash balances. Insider sales and mixed hedge fund activity also characterized the period.
Health Catalyst: Fourth Quarter Earnings Overview
Health Catalyst Inc. reported a net loss of $91 million, or $1.28 per share, for the fourth quarter. Despite adjusted earnings of 8 cents per share missing analyst expectations of 9 cents, the healthcare data analytics company surpassed revenue forecasts with $74.7 million. For the upcoming first quarter, Health Catalyst projects revenues between $68 million and $70 million.
Health Catalyst (HCAT) CEO executes mandated sell-to-cover tax transaction
Health Catalyst (HCAT) CEO Albert Benjamin reported a mandatory "sell to cover" transaction, disposing of 70,455 shares at $1.8481 each to fulfill tax obligations related to vesting restricted stock units. This was not a discretionary trade but a requirement of the company's equity incentive plans. Following this, Benjamin directly holds 1,457,978 shares of Health Catalyst common stock.
Health Catalyst (HCAT) Q4 Earnings: What To Expect
Health Catalyst (HCAT) is set to report its Q4 earnings after market close on Thursday. The market anticipates a 7% year-on-year revenue decline, contrasting with last year's 6% increase. Despite analysts reconfirming estimates, the stock is down 15.5% over the last month, with an average analyst price target significantly higher than its current share price.
Health Catalyst (NASDAQ: HCAT) insider sells 18,270 restricted shares reported
Health Catalyst (NASDAQ: HCAT) reported insider selling activity where Benjamin Albert disposed of 18,270 restricted common shares over two dates in February and March 2026. These dispositions were tied to compensation, and a resale entry for restricted common stock dated March 10, 2026, was also listed. The filing indicates a "Neutral" sentiment regarding the impact of these transactions according to Rhea-AI.
Health Catalyst, AppLovin, PubMatic, and Pegasystems Stocks Trade Up, What You Need To Know
Several software stocks, including Health Catalyst, AppLovin, PubMatic, and Pegasystems, experienced significant jumps in their stock prices. This rally is attributed to renewed investor interest in the software sector, particularly in companies providing practical AI solutions for businesses, following a period where these stocks had lagged. The market is shifting from general AI excitement to a more nuanced view, identifying "AI Winners" and moving past previous fears of disruption.
Health Catalyst, AppLovin, PubMatic, and Pegasystems Stocks Trade Up, What You Need To Know
Several software stocks, including Health Catalyst, AppLovin, PubMatic, and Pegasystems, saw significant jumps, reflecting a broader rally in the software sector. This surge follows a period of underperformance and indicates a shift in investor focus from general AI excitement to software companies offering practical business solutions. Leading firms like Morgan Stanley suggest this trend is driven by targeted enterprise AI adoption, signaling a more mature investment phase in the technology.
Health Catalyst (HCAT) insider registers 20,838 restricted shares for sale
A Form 144 filing indicates that Health Catalyst, Inc. (HCAT) has registered 20,838 restricted shares of common stock for sale on March 2, 2026, through broker Morgan Stanley Smith Barney LLC. These shares were issued as compensation. The filing also details prior restricted-stock sales by Benjamin Landry, totaling 14,387 shares on December 1, 2025, 27,425 shares on December 5, 2025, and 6,317 shares on February 26, 2026.
Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
Health Catalyst (Nasdaq: HCAT) will release its fourth quarter and year-end 2025 operating results on Thursday, March 12, 2026, after market close. The company will host a conference call at 5:00 pm ET on the same day to discuss the results. The call details and webcast information are provided for interested participants.
Bentley Systems, Guidewire Software, Health Catalyst, and Doximity Shares Skyrocket, What You Need To Know
Shares of Bentley Systems, Guidewire Software, Health Catalyst, and Doximity saw significant jumps in the afternoon session as software stocks rebounded from a previous "SaaSpocalypse" sell-off. The rally suggests investors are moving past fears that AI agents would disrupt enterprise software business models, with some now looking for "AI Winners." Health Catalyst, despite its recent volatility and a significant drop year-to-date, saw a 6.2% increase, indicating the market views this news as meaningful.
How to listen to Health Catalyst’s March 12 results call
Health Catalyst (HCAT) is scheduled to release its fourth quarter and year-end 2025 operating results on Thursday, March 12, 2026, after market close, followed by a conference call at 5:00 pm ET. Investors can join the call via dial-in numbers or a live audio webcast, with a replay available for 90 days. The announcement provides key details including access information and outlines recent company history, highlighting a pattern of negative price reactions to positive corporate updates.
Health Catalyst to Announce Fourth Quarter and Year End 2025 Operating Results and Host Conference Call on Thursday, March 12, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its fourth quarter and full year 2025 operating results on Thursday, March 12, 2026, after market close. The company will host a conference call on the same day at 5:00 pm ET to review these results. Details for accessing the call via phone or live audio webcast are provided, with a replay available online for 90 days.
Health Catalyst (NASDAQ: HCAT) insider to sell 13,836 restricted shares via MS
Health Catalyst, Inc. filed a Form 144 indicating an insider's intent to sell 13,836 restricted common shares through Morgan Stanley Smith Barney LLC on March 2, 2026. These shares were issued as compensation. The filing also detailed previous dispositions by Linda Llewelyn, totaling 14,233 shares in late 2025 and early 2026, with associated aggregate proceeds.
Revenue per share of Health Catalyst, Inc. – DUS:2YP
This article provides a brief overview of the "Revenue per share" metric for Health Catalyst, Inc., traded on the Dusseldorf Stock Exchange under the symbol 2YP. It indicates that the market is closed and no trades have occurred for this specific data point. The content appears to be a financial data page from TradingView.
Health Catalyst (HCAT) Form 144: 7,522 restricted shares proposed for sale
Health Catalyst (HCAT) has filed a Form 144, disclosing a proposed sale of 7,522 restricted common shares on February 26, 2026, stemming from a compensation-related plan. The filing also indicates a previous sale of 20,619 restricted shares on December 1, 2025, by the same reporting entity, Jason Alger. Morgan Stanley Smith Barney LLC is listed as the broker for the proposed sale, which will be executed on NASDAQ.
Primecap Management Co. CA Sells 617,620 Shares of Health Catalyst, Inc. $HCAT
Primecap Management Co. CA significantly reduced its stake in Health Catalyst, Inc. (NASDAQ: HCAT) by 31.1%, selling 617,620 shares and now owning 1,369,067 shares valued at $3.9 million. This sale comes as Health Catalyst shares are trading near multi-year lows, with a negative P/E ratio and analysts rating the stock as "Hold." Despite high institutional ownership at 85%, insider ownership has decreased to 2.6% due to recent sales by company executives.
Health Catalyst (HCAT) CEO logs large RSU grants and tax-driven share sale
Health Catalyst (HCAT) CEO Albert Benjamin received substantial RSU and PRSU grants totaling over 968,000 units on February 25, 2026. Shortly after, on February 26, 2026, he sold 13,304 common shares at $1.7478 each to cover tax withholding obligations associated with vested RSUs. This "sell to cover" transaction is described as mandatory rather than a discretionary trade.
